The Benefits Breaking Point: Rising Health Costs, the GLP-1 Dilemma, and How Leaders Can Keep Coverage Affordable, Fair, and Worth Having

[00:00:00] You know that feeling every autumn when the open enrollment packet hits your inbox? Oh yeah, everyone completely dreads it. Right. You open it up, you pour a cup of coffee just to brace yourself, and you skim straight to the premium table. Yeah, looking for the damage. Exactly. And there it is. Like, the creeping realization that your paycheck deduction is going up again. It always does. It does! And you just let out this heavy sigh, you click the exact same plan you had last year, and you essentially just hope you don't get too sick.

[00:00:28] Which is such a wild way to handle health care, you know. But it is a universally dreaded annual ritual. It really is. But what you probably don't realize in that exact moment is that over the last decade, that single line item has secretly eaten almost all of your potential wage growth. We kind of just treat open enrollment like the weather, like something unpleasant that just happens to us. We do. And the problem is that the math behind that ritual is rapidly reaching a breaking point. Right.

[00:00:55] Right. The old corporate playbook of just passively absorbing rate hikes and passing the bill down to employees, well, it's structurally failing. Okay, let's unpack this because the sheer scale of the crisis we are looking at today is staggering. Staggering is definitely the right word for it. So today we are pulling insights from a deeply researched 2026 paper by Dr. Jonathan H. Westover, PhD. It's titled, The Benefits Breaking Point. It's a great paper. Yeah. Really eye opening.

[00:01:21] Yeah. And our mission for this deep dive is to basically look under the hood of your health plan. For the 157 million Americans under 65 who rely on employer sponsored health coverage, we want to map out exactly why those costs are exploding. And maybe more importantly, how the smartest organizations out there are completely tearing up the old playbook to keep coverage fair and, you know, actually worth having. Exactly. Because whether you are an employee just trying to make sense of a shrinking paycheck

[00:01:51] or a leader tasked with designing these benefits for thousands of people, this data affects your bottom line and your daily health. Yeah. The status quo is just financially unsustainable for both parties at this point. So let's start with the sticker shock for 2026 because the numbers in this paper are incredibly sobering. Oh, they really are. Looking at the latest survey data from KFF, it shows that the average family premium has hit $28,303. Which is just a massive number.

[00:02:19] It's huge. And the workers' share of that premium, like what you actually pay, jumped 9% in a single year to almost $7,500. Right. And we have to point out that those averages actually obscure a massive disparity between small firms and large firms. Oh, really? How so? Well, if you work at a small company, the odds are heavily stacked against you. At small firms, 32% of workers are paying more than half of that total family premium out of their own pockets.

[00:02:48] Wow. Over half? Over half. Furthermore, their deductibles are significantly higher, averaging over $2,600 before the insurance even begins to cover significant costs. So you're basically paying thousands just for the privilege of paying thousands more before your benefits even kick in. Exactly. It's really rough. So when we look for the culprits driving this inflation, the paper points to a few systemic drivers, right? Starting with hospital consolidation. Yeah, that's a huge one.

[00:03:14] Because when one massive health system buys up all the competing hospitals and all the independent specialist clinics in like a 50-mile radius, they essentially create a regional monopoly. Right. And then the employer, and by extension the employee, has absolutely no choice but to accept whatever inflated prices that monopoly dictates. It's a trap. It is. And you also have to factor in the explosion of incredibly complex, expensive new therapies. Like the new specialty drugs. Yes, exactly.

[00:03:42] We are seeing these revolutionary treatments for cancer and rare diseases hitting the market, along with the rise of the specialty pharmacies that handle them. Which is obviously amazing for the patients. Oh, they are literal lifesavers. But they come with price tags that can single-handedly destabilize a midsize company's entire benefits budget. Right. And for decades, the default response from employers when they saw these costs escalating was just to eat the cost, right? Like lean on health benefits as a retention tool.

[00:04:09] Yeah. They just absorbed it to keep people around. The text calls this job lock. And I look at job lock like staying in a terribly toxic relationship just because you two share a rent-controlled apartment with a great view. That is a brutally accurate analogy. Right. Like on a spreadsheet, the HR department logs that as retention. But in reality, it's a fragile, unhealthy attachment. You're holding onto people who are disengaged, probably burned out, and only sticking around because they desperately need the co-pays for their family.

[00:04:38] Which completely kills innovation. It does. And the economic reality of that dynamic is thoroughly documented. The paper cites findings from economists Biker and Chandra, which prove that these premium increases don't just stay on the employer's side of the ledger. Meaning the employees pay for it eventually. Exactly. When an employer has to pay more for your health insurance, they compensate by paying you less in your salary. You are funding the rising cost of health care even if you never visit a doctor, simply through foregone raises and stagnant wages over time.

[00:05:07] Wow. It's literally an invisible tax. It really is. Well, to understand how employers are reacting to this immense pressure cooker today, I mean, we have to look at the absolute epicenter of the current crisis. Oh, yes. We have to talk about GLP-1s. Yes. We are talking about GLP-1 weight loss drugs, medications like Wagovi and Zetbound. They represent a perfect microcosm of the benefits breaking point.

[00:05:33] We are watching a real-time collision between a genuine clinical miracle and a brutal financial reality. Because clinically, the results are undeniable. Absolutely. Before we look at the financials, we should probably establish how these actually work because it explains the massive demand. Good idea. So, these drugs mimic a hormone called GLP-1 that your intestines naturally release when you eat. It tells your pancreas to produce insulin, but it also signals your brain that you are full.

[00:06:02] And it physically slows down how fast your stomach empties. Right, which leads to significant weight loss. Huge weight loss. The paper highlights the SELECT trial, which showed these drugs producing 15 to 21 percent weight loss. Which is incredible on its own. But even more critical is the finding of a 20 percent drop in major cardiovascular events, meaning heart attacks and strokes. Yeah, the clinical efficacy is unprecedented. But then you look at the ledger. The cost. The financial impact is staggering the entire system.

[00:06:33] Jefferson Health, which is a massive regional health system, reported losing roughly $180 million in its insurance division recently. $180 million. Yes. And they attributed about a third of that loss entirely to the cost of GLP-1s. That is wild. Because of unsustainable financial hits like that, an estimated 12 million people lost coverage for these drugs between 2025 and 2026. So, we are seeing employers actively panicking.

[00:07:01] Like the University of Missouri, Cigna, HCA Healthcare, they all simply dropped coverage for these drugs. It's completely cut them out. Missouri even put out a statement communicating that if they kept covering them, they would be forced to hike premiums by 28 percent for every single employee on the plan, regardless of whether they use the drug. It's a huge hike. But, wait, I have to push back on this logic. Okay, go for it.

[00:07:24] If these drugs legitimately prevent heart attacks, and treating a heart attack in the ICU is phenomenally expensive, shouldn't employers be practically begging their employees to take them? It seems like it, right? Yeah. Isn't dropping coverage terribly short-sighted? Well, what's fascinating here is the fundamental time horizon mismatch built into employer-sponsored healthcare. Time horizon mismatch. Yeah.

[00:07:50] You are absolutely correct that preventing a heart attack saves a massive amount of money. The issue is that the cost of the drug hits the employer's budget today, every single month, at roughly $1,000 of prescription. Right. It's an immediate recurring cost. Exactly. But the cardiovascular savings accrue over years, sometimes decades. Oh, I see. And modern workers don't exactly stay at jobs for decades anymore. Precisely.

[00:08:16] Because of employee turnover, the employer who pays for the GLP-1 therapy today is statistically very unlikely to be the employer who reaps the financial benefit of the prevented heart attack five years from now. That makes so much sense. It's a tragedy of the commons, almost. It is. Furthermore, the real-world data complicates the math even more. The paper cites research showing that real-world persistence on these medications is astonishingly low. Meaning people don't keep taking them. Right.

[00:08:45] Only about 1 in 12 people actually stay on the therapy for three years. And when they stop, clinical trials show they regained about two-thirds of the weight within a year. Oh, wow. So employers are looking at a massive immediate expense, incredibly low adherence, and fleeting clinical benefits. It makes complete sense why they hit the panic button then. But this GLP-1 dilemma shows us what happens when employers just cut coverage blindly to stop the bleeding. Yeah, and that instinct isn't just isolated to weight loss drugs.

[00:09:14] No, it gets applied to the entire health plan design. When costs go up, broadly, the default reaction for employers is what the industry calls cost shifting. Right. If the pie's getting more expensive, just make the employee eat a larger slice of the bill. Exactly. The survey found 44% of large firms raised worker premiums this past year, and 21% raised deductibles. Which is based on this old theory. The theory behind the high-deductible health plan was always that if employees have to pay more out of pocket,

[00:09:42] they will suddenly become savvy, price-conscious shoppers. Like they'll compare MRI prices the way they compare airline tickets. Exactly. But the research shows this is a massive behavioral failure. Total failure. The paper cites this landmark study by Brat Goldberg where a large company moved its entire workforce to high-deductible plans. And what happened? Employees didn't magically start shopping around for cheaper doctors or negotiating lab fees. They just stopped getting care entirely. Even the important stuff?

[00:10:11] Yes, including highly valuable preventative care. It's like telling someone, hey, to save money on your car maintenance, just stop getting oil changes. That's a great way to put it. Right. You save $50 today, but the engine is going to explode next year and cost you $5,000. It is an incredibly blunt instrument. It really is. And we also have to examine the equity of that approach. Yeah, the fairness aspect. Because flat-dollar premium hikes and high deductibles are inherently regressive.

[00:10:40] A $2,000 deductible might be a minor inconvenience for a senior executive, but it is a full-blown financial catastrophe for a frontline worker. It really forces lower-wage employees to delay filling prescriptions or skip crucial follow-up visits. Exactly. Their chronic conditions go unmanaged until they eventually end up in the emergency room, where the care is 10 times more expensive. So if cost-shifting is just a disaster that delays expensive care, employers clearly need a different model.

[00:11:10] They do. And the paper outlines an alternative called Value-Based Insurance Design, or VBID. VBID. Yes. The core ethos of VBID is that cost-sharing shouldn't be based on the arbitrary price tag of a service, but on its actual clinical value to the patient. So you make the high-value preventative care incredibly cheap, and the low-value unnecessary care expensive. Exactly. The paper highlights a brilliant trial by Aetna to prove this concept. It took a cohort of patients who had just survived a heart attack.

[00:11:40] Okay. Under a normal plan, these patients would have standard copays for their preventive cardiac medications, things like beta blockers and statins. Sure. Just regular pharmacy copays. Right. But Aetna decided to eliminate those copayments entirely, making the drugs completely free to the patient. Wow. I mean, to a corporate finance department focused entirely on the current quarter, giving away expensive medication for free sounds like financial sabotage. It does sound crazy at first.

[00:12:08] But the results completely validated the model. Adherence to the medication improved dramatically because the financial barrier was gone. That makes sense. And the rate of secondary vascular events, meaning second heart attack strokes, plummeted. It actually reduced total health spending. So they saved money by giving it away. Yes. Aetna didn't lose money by making the drugs free. They saved a fortune by keeping those patients out of the hospital.

[00:12:35] Cost sharing should never be a barrier to the exact care you desperately want your employees to receive. That is such a smart approach. Mm-hmm. But, you know, tinkering with the plan design through VBID is a huge step, but it still doesn't solve the underlying problem of the hyperinflated price of the health care itself. No, it doesn't. If employers are going to stop just shifting costs onto us, they have to fundamentally lower the real price of the care.

[00:12:58] And according to the research, this requires them to stop acting like passive payers and start acting like aggressive fiduciary buyers. This represents a seismic shift in the benefits industry. It really does. Most large employers are what we call self-funded. They aren't actually buying traditional insurance policies from a carrier. They're paying the medical claims out of their own corporate assets and simply paying a major carrier and administrative fee to process the paperwork. Right.

[00:13:25] Under a federal law called ERISA, that arrangement makes the employer a fiduciary. And being a fiduciary isn't just a corporate buzzword. It is a strict legal standard. Very strict. It means you are legally obligated to manage the plan's assets prudently and purely in the best interests of the beneficiaries, similar to the legal duty of someone managing a retirement fund. Exactly. And employees are finally starting to hold their employers' feet to the fire on this.

[00:13:50] The paper actually mentions recent lawsuits against massive companies like Johnson & Johnson and Wells Fargo. Yeah, those lawsuits are a huge deal. Employees sued, alleging the companies breached their fiduciary duty by wildly overpaying for generic drugs. Right. And the mechanism they were suing over involves pharmacy benefit managers, or PBMs. The middlemen. Yes. Employers hire these PBMs as middlemen to negotiate drug prices with manufacturers and pharmacies.

[00:14:17] The lawsuits allege that instead of securing the best price for the plan, the PBMs were funneling hidden markups and retaining massive rebates. Wow. Resulting in the employer and the employee paying vastly more than retail price for basic generics. That's infuriating. While those specific early cases faced procedural hurdles, they put every HR department in the country on notice.

[00:14:38] This is especially true now that gag clauses, which are contracts that literally made it illegal for employers to see the real cost of their own claims data, have been outlawed. Suing a middleman is just playing defense, though. True. If employers actually want to go on the offensive and fix the prices, they have to completely change how they negotiate with hospitals. Right. Just look at what happened in Montana. In 2014, the state's employee health plan was facing a projected $28.9 million loss. They were headed for total insolvency.

[00:15:08] A complete disaster. Yeah. But the plan administrator, a CPA named Marilyn Bartlett, decided to act like a true fiduciary. She dropped their PBM to get transparent drug pricing, but her most aggressive move was implementing something called reference-based pricing with the state's hospitals. Reference-based pricing is a total paradigm shift. How does it work? Well, normally a health plan just accepts whatever arbitrary discount a hospital offers off their heavily inflated master price list, which is called the charge master. Right.

[00:15:39] The charge master is basically a work of fiction. The prices have absolutely no grounding in the actual cost of care. Reference-based pricing completely flips the table. So instead of negotiating down from a fake number, you negotiate up from a real one. Exactly. They use Medicare rates as the baseline because Medicare pays based on the actual mathematical cost of delivering the care plus a small, reasonable margin. So Bartlett went to the hospitals and basically said, we aren't playing the discount game anymore.

[00:16:07] We know exactly what Medicare pays for a knee replacement, and we will pay you a fair multiple of that Medicare rate, say 230%. Take it or leave it. Wow. Very bold. Extremely bold. But by enforcing that purchasing discipline, Montana didn't just avoid insolvency. By 2017, they had built a $112 million reserve. They called the hospitals bluff and literally saved the entire system. They sure did.

[00:16:34] But beyond aggressively negotiating prices, employers are also taking the wheel by actively steering employees to better quality care. Yes. Steering is becoming very popular. The paper uses the Walmart Centers of Excellence as the prime example here. Walmart realized a shocking statistic. When their employees were told by a local doctor they needed a joint replacement, about 20% of the time, they didn't actually need the surgery at all. A 20% misdiagnosis rate is terrifying.

[00:17:03] That represents a staggering amount of unnecessary, dangerous, and expensive medical intervention. So Walmart set up a program to intervene. If an employee needed a joint replacement, spinal surgery, or certain cancer treatments, Walmart would steer them away from the average local hospital and direct them to a designated top-tier center of excellence. Places like the Mayo Clinic or Geisinger. Exactly.

[00:17:26] And by funneling volume to these elite centers, Walmart cut the average cost per case by 15%, shortened hospital stays, and dropped readmissions by an incredible 70%. Those are massive improvements. They are. But they enforced this by slapping a massive 50% copay on the employee if they chose to go out of their preferred network. That's a huge penalty. Right. And here's where it gets really interesting, though, and I want to push back on this model just a bit. Go ahead.

[00:17:53] If my HR department tells me exactly which hospital I have to go to, potentially multiple states away, and severely penalizes me financially if I go to the surgeon 10 minutes from my house, I'm going to be furious. Understandably. Nobody likes a narrow network. Doesn't this level of control just destroy employee morale and trigger a revolt? Well, if we connect this to the bigger picture of organizational psychology, you are pointing out a very real risk.

[00:18:17] Like, steering employees absolutely will cause a revolt unless it is paired with robust, tangible support. That is the genius of what Walmart did. They didn't just wield a stick by penalizing the out-of-network choice. They offered a massive carrot. What was the carrot? If you went to the Center of Excellence, Walmart paid for the travel, covered the hotel for the patient and a caregiver, and reduced the medical cost sharing to zero. It is about procedural justice. Ah, okay.

[00:18:45] So you make the high-value path the absolute easiest, cheapest, and most heavily supported path to walk down. Exactly. Employees will accept these trade-offs if the communication is candid and transparent. You have to explain the why behind the design. And you have to ensure the patient feels cared for rather than managed. Which brings us perfectly back to where we started with the GLP-1 dilemma. It does. The smartest employers didn't just ban the weight-loss drugs like Missouri did, but they also didn't just hand them out blindly.

[00:19:14] The paper looks at organizations like Jefferson Health and the state of Connecticut. They took a middle road by implementing structured access. Structured access is really just a form of steering, applied to pharmacy benefits rather than surgery. Right. These organizations communicated to their employees, we will cover these expensive medications, but you have to participate in the clinical telehealth lifestyle and diet program first. Which makes sense. Yeah.

[00:19:39] Patients had to work with a dietician and commit to the behavioral changes that make the drug effective in the long term. Thereby mitigating that massive adherence drop-off we discussed earlier. And it worked, right? Jefferson Health saved $20 million implementing this requirement. And they kept over 90% of the participants actively engaged in the program. They managed the extreme cost without breaking the trust of their people. So what does this all mean? Yeah. Like, for us.

[00:20:05] Whether you are sitting at your kitchen table choosing your family's plan this autumn, or you are the executive designing that plan for a Fortune 500 company, the main takeaway from Westover's research is undeniable. The era of the annual spreadsheet negotiation is over. It's completely over. You cannot just tinker with deductibles, switch carriers every three years, and hope for the best. No. The math no longer allows for passive management.

[00:20:30] Treating health benefits as a multi-year investment in the physical and financial capability of your workforce, rather than just an annoying line-item expense to be minimized, is the only sustainable way forward. Absolutely. It requires total transparency, rigorous fiduciary oversight, and a willingness to actually manage the supply chain of health care, rather than just paying the bills. It is a fundamentally different way of viewing an employer's role in our lives. Which leaves me with a final thought to chew on.

[00:21:00] Let's hear it. If the absolute most successful way to keep these costs down is for our employers to aggressively audit hospital prices, to mandate that we use telehealth dieticians to access our weight loss drugs, and to literally steer us to specific surgical centers across the country, does the line between our employer and our doctor start to get uncomfortably blurry? That is a very valid question. Right.

[00:21:24] Like, at what point does a hyper-efficient, value-based health plan just start feeling like your boss is sitting in the exam room with you? Definitely something to think about the next time you open up that autumn enrollment packet. I don't want to say it. Sometimes your wife is asleep. But then you keep in mind.